Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Raquel S Laureano; Jenny Sprooten; Isaure Vanmeerbeerk; Daniel M Borras; Jannes Govaerts; Stefan Naulaerts; Zwi N Berneman; Benoit Beuselinck; Kalijn F Bol; Jannie Borst; An Coosemans; Angeliki Datsi; Jitka Fučíková; Lisa Kinget; Bart Neyns; Gerty Schreibelt; Evelien Smits; Rüdiger V Sorg; Radek Spisek; Kris Thielemans; Sandra Tuyaerts; Steven De Vleeschouwer; I Jolanda M de Vries; Yanling Xiao; Abhishek D Garg

doi:10.1080/2162402X.2022.2096363

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, An Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris ThielemansSandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao, Abhishek D Garg

Research output: Contribution to journal › Article › peer-review

88 Citations (Scopus)

36 Downloads (Pure)

Abstract

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

Original language	English
Article number	2096363
Journal	Oncoimmunology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2022.2096363
Publication status	Published - 2022

Bibliographical note

Keywords

Antigens, Neoplasm
Cancer Vaccines/therapeutic use
Dendritic Cells
Humans
Immunotherapy
Neoplasms/drug therapy

Access to Document

10.1080/2162402X.2022.2096363Licence: CC BY-NC

86265301Final published version, 2.5 MBLicence: CC BY-NC

Cite this

Laureano, R. S., Sprooten, J., Vanmeerbeerk, I., Borras, D. M., Govaerts, J., Naulaerts, S., Berneman, Z. N., Beuselinck, B., Bol, K. F., Borst, J., Coosemans, A., Datsi, A., Fučíková, J., Kinget, L., Neyns, B., Schreibelt, G., Smits, E., Sorg, R. V., Spisek, R., ... Garg, A. D. (2022). Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology, 11(1), Article 2096363. https://doi.org/10.1080/2162402X.2022.2096363

@article{6e1fa7ab5261416f8eca94ad1bea18d6,

title = "Trial watch: Dendritic cell (DC)-based immunotherapy for cancer",

abstract = "Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.",

keywords = "Antigens, Neoplasm, Cancer Vaccines/therapeutic use, Dendritic Cells, Humans, Immunotherapy, Neoplasms/drug therapy",

author = "Laureano, {Raquel S} and Jenny Sprooten and Isaure Vanmeerbeerk and Borras, {Daniel M} and Jannes Govaerts and Stefan Naulaerts and Berneman, {Zwi N} and Benoit Beuselinck and Bol, {Kalijn F} and Jannie Borst and An Coosemans and Angeliki Datsi and Jitka Fu{\v c}{\'i}kov{\'a} and Lisa Kinget and Bart Neyns and Gerty Schreibelt and Evelien Smits and Sorg, {R{\"u}diger V} and Radek Spisek and Kris Thielemans and Sandra Tuyaerts and {De Vleeschouwer}, Steven and {de Vries}, {I Jolanda M} and Yanling Xiao and Garg, {Abhishek D}",

note = "{\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/2162402X.2022.2096363",

language = "English",

volume = "11",

journal = "Oncoimmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

Laureano, RS, Sprooten, J, Vanmeerbeerk, I, Borras, DM, Govaerts, J, Naulaerts, S, Berneman, ZN, Beuselinck, B, Bol, KF, Borst, J, Coosemans, A, Datsi, A, Fučíková, J, Kinget, L, Neyns, B, Schreibelt, G, Smits, E, Sorg, RV, Spisek, R, Thielemans, K , Tuyaerts, S, De Vleeschouwer, S, de Vries, IJM, Xiao, Y & Garg, AD 2022, 'Trial watch: Dendritic cell (DC)-based immunotherapy for cancer', Oncoimmunology, vol. 11, no. 1, 2096363. https://doi.org/10.1080/2162402X.2022.2096363

TY - JOUR

T1 - Trial watch

T2 - Dendritic cell (DC)-based immunotherapy for cancer

AU - Laureano, Raquel S

AU - Sprooten, Jenny

AU - Vanmeerbeerk, Isaure

AU - Borras, Daniel M

AU - Govaerts, Jannes

AU - Naulaerts, Stefan

AU - Berneman, Zwi N

AU - Beuselinck, Benoit

AU - Bol, Kalijn F

AU - Borst, Jannie

AU - Coosemans, An

AU - Datsi, Angeliki

AU - Fučíková, Jitka

AU - Kinget, Lisa

AU - Neyns, Bart

AU - Schreibelt, Gerty

AU - Smits, Evelien

AU - Sorg, Rüdiger V

AU - Spisek, Radek

AU - Thielemans, Kris

AU - Tuyaerts, Sandra

AU - De Vleeschouwer, Steven

AU - de Vries, I Jolanda M

AU - Xiao, Yanling

AU - Garg, Abhishek D

PY - 2022

Y1 - 2022

N2 - Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

AB - Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

KW - Antigens, Neoplasm

KW - Cancer Vaccines/therapeutic use

KW - Dendritic Cells

KW - Humans

KW - Immunotherapy

KW - Neoplasms/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85133437819&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2022.2096363

DO - 10.1080/2162402X.2022.2096363

M3 - Article

C2 - 35800158

SN - 2162-4011

VL - 11

JO - Oncoimmunology

JF - Oncoimmunology

IS - 1

M1 - 2096363

ER -

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this